Clinical Trials

529 enrolled 12 charts 1 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

465 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02477696 2026-05-27

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03462719 2026-05-08

GLOW

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01886872 2026-05-04

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02947347 2026-03-17

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

445 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03112174 2025-07-22

SYMPATICO

366 enrolled 45 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01776840 2025-07-08

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

523 enrolled 28 charts

Lymphoma, Mantle-Cell

NCT01974440 2025-05-25

SELENE

403 enrolled 23 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03734016 2025-03-30

ALPINE

652 enrolled 27 charts 1 FDA

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

838 enrolled 16 charts

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03053440 2024-10-26

ASPEN

201 enrolled 19 charts 1 FDA

Waldenstrom Macroglobulinemia

NCT01724346 2024-09-19

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

269 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02703272 2022-12-02

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Phase 3 Terminated

72 enrolled 36 charts

Lymphoma, Non-Hodgkin

NCT02301156 2022-05-20

GENUINE

126 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02165397 2021-03-03

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

181 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia

NCT02264574 2020-09-21

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

229 enrolled 29 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01611090 2020-03-03

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

578 enrolled 21 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01578707 2019-12-18

RESONATE™

391 enrolled 14 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01973387 2018-07-24

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

160 enrolled 12 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01646021 2018-01-19

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

280 enrolled 26 charts

Lymphoma, Mantle-Cell

NCT01722487 2017-11-30

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

269 enrolled 14 charts